Medical device manufacturer Bluejay Diagnostics reported it needs to raise at least $20 million to avoid bankruptcy.
Medical device manufacturer Bluejay Diagnostics reported it needs to raise at least $20 million to avoid bankruptcy as the Acton-based firm navigates the post-startup phase when early funding begins to run out before products reach the market.
“Financially, Bluejay is on quite good standing,” Bluejay President and CEO Neil Dey wrote in an email to WBJ.
Bluejay’s sole product, a biomarker detection platform named Symphony, is still undergoing research and development. Because Symphony has not received U.S. Food and Drug Administration clearance, Bluejay has not been able to sell it, and thus, has been unable to generate operating income since its inception, according to the firm's annual report filed with the U.S. Securities and Exchange Commission on Friday.
As of Dec. 31, Bluejay held approximately $5.2 million in cash and cash equivalents, yet the firm expects to incur significant operating losses again in 2026 and 2027. Bluejay said it needs to raise at least $20 million by the end of fiscal 2027 in order to meet its goal of applying for FDA clearance by the end of that year.
Bluejay’s need to raise money is a common problem for life sciences startups. This financial crunch time is a pivotal point where companies either take off or fail,
known as the Valley of Death.
Bluejay reports the market price of its common stock has fallen more than 99.9% since going public on the Nasdaq in November 2021. The firm reported in its annual filing that its stock price had decreased by more than 80% each year in 2022, 2023, 2024, and 2025.
In October, Bluejay sold 2.25 million shares of common stock for $2.00 per share, receiving a warrant for shareholders to purchase an additional 4.5 million shares at the same price, according to an Oct. 9 press release.
“If we do not raise additional capital, we expect to run out of available cash resources in the third quarter of 2026,” the filing said.
If Bluejay does run out of cash, the firm may need to start liquidation processes under U.S. bankruptcy laws, the filing said, “which could cause holders of our common stock to recoup little, if any, value for their shares.”
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare, manufacturing, and higher education industries.
